Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
Glycores 2000 Srl currently has 1 pending office action in the Biotechnology & Pharmaceuticals technology area. This single matter is being examined by a distinct examiner, ALAOUIE, ALI MUSTAFA. As the busiest examiner for the company, ALAOUIE, ALI MUSTAFA is responsible for 1 pending office action, which is the only active matter in the portfolio. The prosecution is concentrated in a distinct art unit, reflecting a specific technical focus for this filing.
For a practitioner, this means the entire prosecution effort is centered on one interaction. With a distinct examiner and a distinct art unit, there is no diversification of the workload. The 1 pending office action in the Biotechnology & Pharmaceuticals sector will be decided based on the specific requirements of ALAOUIE, ALI MUSTAFA. This focused profile suggests that the company's current patent activity is limited to a single, specific project or technology. Success in this 1 pending office action is essential for the company's immediate intellectual property goals in the biotechnology field.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Multi-statute (no §101) | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| ALAOUIE, ALI MUSTAFA | 1 | — | — |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18849545 | TOPICAL PHARMACEUTICAL COMPOSITION WITH ANTI-INFLAMMATORY AND ANALGESIC ACTIVITY AND USES THEREOF | ALAOUIE, ALI MUSTAFA | — |
| Art Unit | Apps |
|---|---|
| 1614 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18849545 | TOPICAL PHARMACEUTICAL COMPOSITION WITH ANTI-INFLAMMATORY AND ANALGESIC ACTIVITY AND USES THEREOF | ALAOUIE, ALI MUSTAFA | 1614 | §103§112 | Non-Final OA | — | Pending | Sep 23, 2024 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialGlycores 2000 Srl has 1 pending office actions as of October 2026, spread across 1 art units and 1 examiners.
Ali Mustafa Alaouie has the most, with 1 of Glycores 2000 Srl's pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
